Germfree mice associated with Clostridium difficile developed intestinal disease characterized by polymorphonuclear cell infiltration of the lamina propria, diarrhea, and cecal cytotoxin concentrations positive at a 106 dilution. The numbers of viable bacteria never exceeded 1010 colony-forming units per g (dry weight). Despite the high toxin levels and chronic inflammation over a 30-day period, the mortality rate was low (<2%). Daily treatment of these animals with two oral doses of 2 mg of vancomycin resulted in stool levels of >200 tig/ml, well in excess of the minimum inhibitory concentration for C. difficile. This therapy decreased viable cell density by 2 to 3 logs and increased the spore counts from 1058 to 1078 colony-forming units per g (dry weight) by day 7, and animals were free of detectable toxin. However, once therapy was stopped, viable bacteria and spore counts and cytotoxin concentrations returned to previous levels. Treatment of mice with concentrations of clindamycin shown to be inhibitory in vitro had no effect on C. difficile toxin titers or bacterial counts, although the appearance of a clindamycin-resistant population was noted. These data indicate that vancomycin, given orally, decreases the concentration of toxin, but C. difficile survive as spores. By contrast, large populations of vegetative cells and high cytotoxin levels persist when clindamycin is used, even at an inhibitory concentration.
The role of Clostridium difficile in antibioticassociated colitis (AAC) has been well established by recent studies. This work has shown that feces from humans or hamsters with AAC contain a cytopathic toxin which can be neutralized with monovalent antiserum (4) . C. dif ficile are believed to be the source of this cytotoxin, since they are isolated at a high rate from stools containing the toxin (1), and C. difficile produce a similar or identical toxin in vitro. The role of this toxin in the pathogenesis of colitis was further clarified by reproducing the disease in experimental animals by intracecal inoculation of C. difficile cell-free supernatant (3) or the partially purified cytotoxin (10) .
A curious feature of the pathogenesis of C. difficile is that these microbes appear to cause enteric disease almost exclusively in individuals given antimicrobial agents. This observation applies to both humans and experimental animals.
Paradoxically, AAC is treated with another antibiotic, vancomycin.
The purpose of the present report was to study the in vivo interrelationship between antibiotics and C. difficile. Gnotobiotic mice were employed as a nonlethal experimental model in which C. difficile populations could be monitored over extended periods without interference from other microbial species. The agents tested were clindamycin, which is a major cause of this complication in humans, and vancomycin, which has become a favored therapeutic modality.
MATERIALS AND Cytotoxicity assay. C. difficile toxin titers were assayed by using a modification of the cytotoxicity assay described by Chang et al. (5) . Intestinal contents were centrifuged at 10,000 x g for 20 min, and the supernatant was filtered through a 0.45-,Lm filter. Serial dilutions of the filtrates were made by using sterile phosphate-buffered saline, and portions of each dilution were added to WI-38 cells grown in medium 199 and incubated at 37°C for 24 h. The results were expressed as the greatest dilution showing cytopathic changes of at least 50% of the cells in the monolayer.
Experimental design. Six groups of 10 to 30 animals were associated with C. difficile. Mice in the first group were sacrificed at sequential intervals for bacteriological and histological evaluation. A second group received vancomycin at a dose of 2 mg twice daily by orogastric intubation, and a third group received clindamycin in the drinking water at a concentration of 10 ,tg/ml. An additional group of animals was associated with E. coli and received vancomycin as described above. Two groups of mice were first associated with B. fragilis and subsequently with C. difficile. These two groups received clindamycin at a concentration of 10 ,yg or 100 ,ug/ml, respectively, in the drinking water. All groups were monitored for total bacterial counts, C. difficile toxin levels, and spore counts. Randomly selected animals from each group were sacrificed for histological evaluation. Stool levels of clindamycin and vancomycin were assayed by using a hemolysis inhibition assay (8) .
RESULTS
Monoassociation with C. difficile. Bacteriological analysis of pooled intestinal contents from two mice at each sampling time indicated that C. difficile could be detected along the entire length of the intestinal tract from the duodenum to the rectum (Table 1) . Levels of viable C. difficile cells at 24 h after association ranged from 104.6 CFU/g (dry weight) in duodenum contents to 1094 CFU/g (dry weight) in the contents from the rectum. Little change in the viable bacterial population density occurred over the next 2 days, although cecal contents consistently yielded the highest intestinal levels of C. difficile after day 3. The levels of C. difficile in the small intestinal contents were not thought to necessarily represent colonization per se; since mice are coprophagic, these counts may simply reflect ingestion of C. difficile in feces. No significant changes in viable cell density in intestinal segment contents were detected after day 3. The number of spores in cecal contents was also quite consistent, at 105.6 CFU/g (dry weight).
Monoassociated mice appeared healthy during the course of the experiment, with the exception of persistent watery stools. Despite diarrhea, animals continued to thrive, gain weight, and consume water and food at a rate comparable to age-matched, unassociated, germfree animals from the same colony. At necropsy, all organs were comparable to those of unassociated animals with the exception of the large intestine and cecum. C. difficile-associated mice had ceca which were considerably smaller than those from germfree animals. A modest decrease in cecal size was first noticed on day 3 after association, and by day 7 the ceca were approximately 1/3 the size of those obtained from germfree animals. No hemorrhagic lesions were seen in the intestinal tract of C. difficile-associated mice, and blood cultures were uniformly negative.
Microscopic examination revealed minimal changes in the small intestine. Examinations of the large bowel revealed a persistent inflammation which was initially noted on day 2, became progressively more intense until day 7, and gradually subsided thereafter (Fig. 1) . The inflammation was characterized by polymorphonuclear cell infiltration and edema of the lamina propria. Despite the intensity of the inflammation, only 1 of the 30 animals died during C. difficile association. Cytotoxin assays of cecal contents and feces obtained before C. difficile association were negative. After association, these were positive at a 106 dilution.
Treatment of C. difficile-associated mice with vancomycin. Vancomycin administration produced a decrease in the viable cell density of C. difficile from i0" CFU/g (dry weight) to 1071 CFU/g (dry weight) of the cecal contents (Fig.  2) . Pooled cecal contents had a vancomycin concentration of >200 jig/ml, which is well in excess of the minimum inhibitory concentration against this strain of C. difficile (minimum inhibitory concentration = 0.5 jig/ml). The concentration of spores increased from 1058 CFU/g (dry weight) before treatment to 107.8 CFU/g (dry weight) during vancomycin therapy. These relatively high spore counts were almost equal to the viable cell counts and suggested that C. difficile persisted during vancomycin treatment primarily as spores. The gradual decrease in both viable cell density and spore counts (Fig.  2) suggests a washout effect for a static bacterial culture. Interestingly, cecal toxin titers decreased from a positive response at a 106 dilution to an undetectable level within 24 h after initiation of vancomycin therapy. These data C. DIFFICILE IN GNOTOBIOTIC MICE 279 indicate that, despite the absence of detectable toxin, C. difficile can persist in large numbers during vancomycin therapy.
Additional animals were associated with C. difficile for 5 days and then given vancomycin for 7 days (Fig. 3) . Viable counts, spore counts, and toxin levels for C. difficile duplicated the earlier results. When the antimicrobial agent was discontinued, toxin levels and viable bacterial counts returned to pretreatment levels, and the animals redeveloped the diarrheal symptoms seen before treatment. These results indicate that C. difficile not only survives during vanco- To determine whether a competing microflora would alter the establishment of C. difficile after vancomycin treatment, a group of mice were associated with E. coli before C. difficile was added to the microflora. Cultures of pools of fecal material from two to three animals revealed that both species established in the large intestine in high numbers, with C. difficile being present at 1090 CFU/g (dry weight) and E. coli at 10'0 CFU/g (dry weight). As in previous experiments, treatment of these mice with vancomycin resulted in a decline in both the C. difficile population and cytotoxin levels. No change in the numbers of E. coli was seen during therapy. The C. difficile population and toxin levels returned to pretreatment values within 24 h after vancomycin was discontinued.
Effect of clindamycin on C. difficile in vivo. C. difficile-associated mice were given clindamycin in their drinking water to evaluate the effects of an antimicrobial known to induce AAC. Preliminary experiments showed that no change in viable cell density, spore counts, toxin titer or looseness or frequency of stools occurred during clindamycin administration. Two additional groups of mice were then associated with a combination of C. difficile and B. fragilis to determine whether the presence of an additional microbe would alter the effect of clindamycin on C. difficile. Clindamycin was administered to associated mice at a concentration of either 10 or 100 pg/ml in the drinking water. In both groups, the B. fragilis population measured in fecal samples decreased from 1095 CFU/g (dry weight) to 105 CFU/g (dry weight) within 48 h after initiating clindamycin (Fig. 4) . C. difficile difficile isolates from these animals before and during therapy showed that 19 of 20 pretreatment isolates were sensitive to 1 ,ig of clindamycin per ml, whereas 11 of 20 isolates obtained during treatment were resistant to 64 fg/ml.
Culture of pooled feces from these animals onto media incorporating 10 ,ig of clindamycin per ml (Fig. 5) showed that the number of clindamycinresistant organisms increased from undetectable levels before clindamycin treatment to 107.8 CFU/g (dry weight) by day 5 of antimicrobial exposure.
These data suggest either that C. difficile rapidly develop resistance to clindamycin or that a low percentage of resistant organisms in these mice become dominant during antimicrobial therapy.
DISCUSSION
This study evaluates the effects of monoassociation of germfree mice with C. difficile. The animals developed diarrhea and had cytotoxin in their stools and an acute, nonlethal colitis characterized by intense polymorphonuclear cell infiltration and edema of the lamina propria. Previous studies have implicated C. difficile as a cause of antibiotic-induced cecitus in hamsters with a conventional microflora (4, 9) . Major differences between the disease in monoassociated gnotobiotic mice and in conventional hamsters given antibiotics are the rapidly lethal course and the intense mucosal hemorrhage seen in conventional hamsters. With human patients, the disease course and histological changes in colonic mucosa appear more comparable to those produced in gnotobiotic mice. A prior report indicated that C. difficile caused colonic lesions in germfree hares but did not cause pathological change in monoassociated, germfree mice, rats, or rabbits (6) . The discrepancy in observations with germfree mice in the two studies is unexplained except for vagaries in the mouse strains or the C. difficile isolate used.
C. difficile persisted in both monoassociated and diassociated gnotobiotic animals despite stool levels of the antibiotic which were well in excess of the in vitro minimum inhibitory concentration. However, during vancomycin therapy the concentrations of C. difficile decreased, the cytotoxin could not be detected, the diarrhea subsided, and the intensity of inflammation decreased. The number of spores increased during vancomycin treatment and appeared to account for virtually all the C. difficile enumerated.
The failure of vancomycin to eradicate C. difficile is of interest in view of clinical relapses. In most instances, vancomycin gives a prompt clinical improvement of pseudomembranous colitis due to C. difficile (11) . Nevertheless, some patients have a persistence of the organisms despite vancomycin levels in the stool which are several hundred-fold higher than the minimum inhibitory concentration (unpublished data). Nearly all patients respond to vancomycin, but some of these patients experience a recurrence of symptoms in association with a reappearance of the cytotoxin. Our studies with gnotobiotic mice suggest that spores survive during vancomycin administration and recolonize the gut when the drug is discontinued. The presence of E. coli did not prevent reestablishment of C. difficile as a dominant component of the flora. However, it is known that vancomycin administration to hamsters with a conventional flora results in the lethal cecitis when the antimicrobial agent is discontinued. These animals have no detectable cytotoxin, no diarrhea, and no colonic lesions while vancomycin is administered. When vancomycin is discontinued, these animals develop large populations of vancomycin-sensitive C. difficile, have cytotoxin concentrations which are positive at i0-5 to 1O-' dilutions, and expire after 5 to 7 days (2). These observations in conventional hamsters appear comparable to those in gnotobiotic mice given vancomycin except for the rapidly lethal outcome.
Administration of clindamycin to monoassociated gnotobiotic mice did not result in any change in the C. difficile population or in the concentrations of the cytotoxin. The addition of a clindamycin-sensitive strain of B. fragilis to the flora had no important effect on either the concentrations of C. difficile or of cytotoxin. Counts of B. fragilis in these diassociated animals decreased with clindamycin administration, as would be anticipated. However, this decrease also had no impact on the concentrations of C. difficile or the levels of cytotoxin.
The persistence of C. difficile during clindamycin therapy is curious in view of the fact that the strain employed was sensitive to clindamycin, and antimicrobial levels in the stools were well in excess of the minimum inhibitory concentrations. A partial explanation was seen in the increased numbers of antibiotic-resistant cells that were present. These data suggest that C. difficile may rapidly develop resistance to clindamycin or that the inoculum contains a low percentage of resistant organisms which emerge as a greater portion of the flora in the face of antimicrobial pressure. These data are consistent with observations that clindamycin may cause antibiotic-induced colitis in both human patients and hamsters during the course of treatment (2, 3). 
